The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial
Open accessAbstract
Background Findings of large randomised trials have shown that lowering LDL cholesterol with statins reduces vascular morbidity and mortality rapidly, but limited evidence exists about the long-term efficacy and safety of statin treatment. The aim of the extended follow-up of the Heart Protection Study (HPS) is to assess long-term efficacy and safety of lowering LDL cholesterol with statins, and here we report cause-specific mortality and major morbidity in the in-trial and post-trial periods.Methods 20,536 patients at high risk of vascular and non-vascular outcomes were allocated either 40 mg simvastatin daily or placebo, using minimised randomisation. Mean in-trial follow-up was 5·3 years (SD 1·2), and post-trial follow-up of surviving patients yielded a mean total duration of 11·0 years (SD 0·6). The primary outcome of the long-term follow-up of HPS was first post-randomisation major vascular event, and analysis was by intention to treat. This trial is registered with ISRCTN, number 48489393.Findings During the in-trial period, allocation to simvastatin yielded an average reduction in LDL cholesterol of 1·0 mmol/L and a proportional decrease in major vascular events of 23% (95% CI 19-28; p<0·0001), with significant divergence each year after the first. During the post-trial period (when statin use and lipid concentrations were similar in both groups), no further significant reductions were noted in either major vascular events (risk ratio [RR] 0·95 [0·89-1·02]) or vascular mortality (0·98 [0·90-1·07]). During the combined in-trial and post-trial periods, no significant differences were recorded in cancer incidence at all sites (0·98 [0·92-1·05]) or any particular site, or in mortality attributed to cancer (1·01 [0·92-1·11]) or to non-vascular causes (0·96 [0·89-1·03]).Interpretation More prolonged LDL-lowering statin treatment produces larger absolute reductions in vascular events. Moreover, even after study treatment stopped in HPS, benefits persisted for at least 5 years without any evidence of emerging hazards. These findings provide further support for the prompt initiation and long-term continuation of statin treatment.Funding UK Medical Research Council, British Heart Foundation, Merck & Co, Roche Vitamins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a timeframe during which a clinical benefit of lipid-lowering therapy would not be expected to emerge 10”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Heart Protection Study and Cholesterol Treatment Trialists’ Collaborators meta-analyses have demonstrated that statins provide consistent cardiovascular benefits and all-cause mortality reduction for patients [6, 7].”
In the citing paper
“Beneficial effects are retained over longterm follow-up.427”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [427]
In the citing paper
“However, in managing dyslipidemia expressed by hypertriglyceridemia, the non-HDL-C level is more useful than the LDL-C level. This has been reported in a number of studies177–179, 623, 624, 626, 627, 647).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [627]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
Jacobs, D. R., Blackburn, H., HIGGINS, M. W., REED, D. M., Iso, H., McMillan, G. C., Neaton, J. D., Nelson, J., Potter, J., & Rifkind, B. M. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 720
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA · doi:10.1001/jama.1996.03530250059028 · Cited by 378
Should there be a moratorium on the use of cholesterol lowering drugs?
Smith, G. D., & Pekkanen, J. (1992) · British medical journal · doi:10.1136/bmj.304.6824.431 · Cited by 357
Holdaas, H., Fellström, B., Cole, E., Nyberg, G., OLSSON, A. G., Pedersen, T. R., Madsen, S., Grönhagen‐Riska, C., Neumayer, H. ‐., Maes, B., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01105.x · Cited by 346
Strandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 329
Cited by
Sorted by citations
Items 101–200 of 377
Zhao, W., An, Z., Hong, Y., Zhou, G., Guo, J., Zhang, Y., Yang, Y., Ning, X., & Wang, J. (2016) · BMC Neurology · doi:10.1186/s12883-016-0561-z · Cited by 55
Egom, E. E. A., & Hafeez, H. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.10.005 · Cited by 57
Adhikari, A., Tripathy, S., Chuzi, S., Peterson, J., & Stone, N. J. (2021) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.10.007 · Cited by 52
Advances in statin adverse reactions and the potential mechanisms: A systematic review
Zeng, W., Deng, H., Luo, Y., Zhong, S., Huang, M., & Tomlinson, B. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.020 · Cited by 58
The association between statin use and risk of age-related macular degeneration
Ma, L., Wang, Y., Du, J., Wang, M., Zhang, R., & Fu, Y. (2015) · Scientific Reports · doi:10.1038/srep18280 · Cited by 50
Dodani, S. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s2915 · Cited by 49
Zhang, X., Liu, J., Wang, M., Qi, Y., Sun, J., Liu, J., Wang, Y., Hao, Y., Li, Y., Zhou, M., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.06.011 · Cited by 49
Huhn, G. D., Shamblaw, D., Baril, J.-G., Hsue, P. Y., Mills, B. L., Nguyen-Cleary, T., McCallister, S. H., & Das, M. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz472 · Cited by 51
Ponce, O. J., Larrea-Mantilla, L., Hemmingsen, B., Serrano, V., Rodríguez‐Gutiérrez, R., Spencer‐Bonilla, G., Álvarez‐Villalobos, N. A., Benkhadra, K., Haddad, A., Gionfriddo, M. R., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00195 · Cited by 48
Martelli, E., Enea, I., Zamboni, M., Federici, M., Bracale, U. M., Sangiorgi, G., Martelli, A. R., Messina, T., & Settembrini, A. M. (2023) · Diagnostics · doi:10.3390/diagnostics13142356 · Cited by 44
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 48
Ferket, B. S., van Kempen, B. J. H., Heeringa, J., Spronk, S., Fleischmann, K. E., Nijhuis, R. L. G., Albert Hofman, D., Steyerberg, E. W., & Hunink, M. G. M. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001361 · Cited by 43
Jing, Z., Yuan, W.-Q., Wang, J., Ni, R., Qin, Y., Mao, Z., Wei, F., Song, C.-L., Zheng, Y.-F., Cai, H., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.001 · Cited by 66
The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease
Ference, B. A., & Mahajan, N. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0312-1 · Cited by 41
Calvert, S., Dempsey, R. C., & Povey, R. (2019) · Obesity Reviews · doi:10.1111/obr.12797 · Cited by 40
Nabatov, A. A., Pollakis, G., Linnemann, T., Paxton, W. A., & de Baar, M. P. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000470 · Cited by 40
Shift of statin use towards the elderly in 1995−2005: a nation‐wide register study in Finland
Ruokoniemi, P. T., Helin‐Salmivaara, A., Klaukka, T., Neuvonen, P. J., & Huupponen, R. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03258.x · Cited by 39
Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Capmany, R. P., Ibanez, M. O., & Pesquer, X. J. (2010) · Current Cardiology Reviews · doi:10.2174/157340310791658712 · Cited by 39
Are statins really wonder drugs?
Grover, H. S., Luthra, S., & Maroo, S. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2013.05.016 · Cited by 38
Baker, J. V., Hullsiek, K. H., Prosser, R. A., Duprez, D. A., Grimm, R. H., Tracy, R. P., Rhame, F. S., Henry, K., & Neaton, J. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046894 · Cited by 37
Krane, V., Schmidt, K.-R., Gutjahr-Lengsfeld, L., Mann, J. F. E., März, W., Swoboda, F., & Wanner, C. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.033 · Cited by 38
Kohli, P., & Cannon, C. P. (2012) · Clinical Cardiology · doi:10.1002/clc.22066 · Cited by 37
Chen, J.-M., Chang, C.-W., Chang, T., Hsu, C.-C., Horng, J., & Sheu, W. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088434 · Cited by 36
Sundararaj, K. P., Samuvel, D. J., Li, Y., Nareika, A., Slate, E. H., Sanders, J. J., Lopes-Virella, M. F., & Huang, Y. Q. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0108064 · Cited by 35
Lv, H., Jin, D., Liu, M., Liu, Y., Wang, J., & Geng, D.-F. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.006 · Cited by 34
Joharatnam‐Hogan, N., Alexandre, L., Yarmolinsky, J., Lake, B., Capps, N. E., Martin, R. M., Ring, A. E., Cafferty, F. H., & Langley, R. E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01023-z · Cited by 34
Crosstalk between Statins and Cancer Prevention and Therapy: An Update
Grabarek, B. O., Boroń, D., Morawiec, E., Michalski, P., Palazzo-Michalska, V., Pach, Ł., Dziuk, B., Świder, M., & Zmarzły, N. (2021) · Pharmaceuticals · doi:10.3390/ph14121220 · Cited by 34
Vascular memory: can we broaden the concept of the metabolic memory?
Jermendy, G. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-44 · Cited by 36
Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention
Kohli, P., Whelton, S. P., Hsu, S., Yancy, C. W., Stone, N. J., Chrispin, J., Gilotra, N. A., Houston, B. A., Ashen, M. D., Martin, S. S., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001098 · Cited by 32
Progress update: Pharmacological treatment of Alzheimer’s disease
Hogan, D. B. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a931 · Cited by 32
A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
Alla, V. M., Agrawal, V., DeNazareth, A., Mohiuddin, S., Ravilla, S., & Rendell, M. (2013) · Drugs · doi:10.1007/s40265-013-0072-9 · Cited by 33
Jowett, S. M., Barton, P. M., Roalfe, A. K., Fletcher, K., Hobbs, R. F., McManus, R. J., & Mant, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182625 · Cited by 32
Merat, S., Poustchi, H., Hemming, K., Jafari, E., Radmard, A.-R., Nateghi, A., Khuzani, A. S., Khoshnia, M., Marshall, T. P., & Malekzadeh, R. (2015) · PubMed · Cited by 31
Atochina‐Vasserman, E. N., Goncharov, D. A., Volgina, A., Milavec, M., James, M. L., & Krymskaya, V. P. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0203rc · Cited by 30
Joo, M. K., Park, J., & Chun, H. J. (2017) · Digestive Diseases · doi:10.1159/000480149 · Cited by 30
Pharmacogenomics discovery and implementation in genome‐wide association studies era
Ni, X., Zhang, W., & Huang, R. S. (2012) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1199 · Cited by 29
Statins and their interactions with other lipid-modifying medications: safety issues in the elderly
Ho, C. K. M., & Walker, S. W. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611428486 · Cited by 29
Luo, Z., Zhang, Y., Gu, J., Feng, P., & Wang, Y. (2015) · Current Therapeutic Research · doi:10.1016/j.curtheres.2015.02.001 · Cited by 28
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes
Kytö, V., Rautava, P. T., & Tornio, A. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac064 · Cited by 28
Xiao, Y., Jia, W., Jin, Y., & Zhen, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087019 · Cited by 28
Gilbert, R. M., Al-Janabi, A., Tomkins‐Netzer, O., & Lightman, S. (2017) · Porto Biomedical Journal · doi:10.1016/j.pbj.2017.01.006 · Cited by 28
HMG CoA reductase inhibitors (statins) to treat Epstein–Barr virus-driven lymphoma
Cohen, J. I. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602561 · Cited by 28
Nazari, I. S., & Feinstein, M. J. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00098-22 · Cited by 29
Carlsson, A. C., Wändell, P. E., Gašević, D., Sundquist, J., & Sundquist, K. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.005 · Cited by 27
Rake, C., Gilham, C., Bukasa, L., Ostler, R., Newton, M., Wild, J. P., Aigret, B., Hill, M., Gillie, O. J., Nazareth, I., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24100 · Cited by 29
Current and Future Treatments of Vascular Cognitive Impairment
Ip, B. Y. M., Ko, H., Lam, B. Y. K., Au, L. W. C., Lau, A. Y. L., Huang, J., Kwok, A. J., Leng, X., Cai, Y., Leung, T. W. H., et al. (2024) · Stroke · doi:10.1161/strokeaha.123.044174 · Cited by 27
Dudum, R., Juraschek, S. P., & Appel, L. J. (2019) · Patient Education and Counseling · doi:10.1016/j.pec.2019.05.005 · Cited by 28
Riedmaier, A. E., Burt, H. J., Abduljalil, K., & Neuhoff, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.669 · Cited by 25
Long-term follow-up of lipid-lowering trials
Packard, C. J., & Ford, I. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000230 · Cited by 24
Vijayaraghavan, K., Baum, S. J., Desai, N. R., & Voyce, S. J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1308173 · Cited by 24
Ennezat, P. V., Guerbaaï, R.-A., Maréchaux, S., Jemtel, T. H. L., & François, P. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001345 · Cited by 24
Nylen, E. S., Faselis, C. J., Kheirbek, R., MYERS, J. N., Panagiotakos, D. B., & Kokkinos, P. F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1431 · Cited by 23
Udell, J. A., Scirica, B. M., Braunwald, E., Raz, I., Steg, P. G., Davidson, J. A., Hirshberg, B., & Bhatt, D. L. (2012) · Clinical Cardiology · doi:10.1002/clc.22032 · Cited by 23
Avritscher, E. B. C., Mosquera, R. A., Tyson, J. E., Pedroza, C., Samuels, C. L., Harris, T. S., Gomez-Rubio, A. M., Navarro, F. A., Moody, S., & Beyda, R. M. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.10.035 · Cited by 22
Beyond statins: what to expect from add-on lipid regulating therapy?
Laufs, U., Weintraub, W., & Packard, C. J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht213 · Cited by 22
Brotons, C., Moral, I., Fernández, D., Puig‐Asensio, M., Calvo‐Bonacho, E., Muñoz, P., Romero, C. C., & Quevedo-Aguado, L. (2018) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.05.002 · Cited by 22
Ezetimibe plus simvastatin for the treatment of hypercholesterolemia
Gryn, S. E., & Hegele, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041504 · Cited by 21
Tattersall, M. C., Gangnon, R. E., Karmali, K. N., Cullen, M. W., Stein, J. H., & Keevil, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059309 · Cited by 21
Blazing, M. A., Giugliano, R. P., de Lemos, J. A., Cannon, C. P., Tonkin, A. M., Ballantyne, C. M., Lewis, B. S., Musliner, T. A., Tershakovec, A. M., Lokhnygina, Y. V., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.004 · Cited by 21
Michos, E. D., Long, S., Blaha, M. J., & Blumenthal, R. S. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s8101 · Cited by 20
Latest advances on interventions that may prevent, delay or ameliorate dementia
Wilson, D., Peters, R. K., Ritchie, K. A., & Ritchie, C. W. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310397636 · Cited by 20
Hamrefors, V., Orho‐Melander, M., Krauss, R. M., Hedblad, B., Almgren, P., Berglund, G. L., & Melander, O. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p001792 · Cited by 21
Intracervical Foley balloon catheter for cervical ripening and labor induction: A review
Greenberg, V., & Khalifeh, A. (2015) · Seminars in Perinatology · doi:10.1053/j.semperi.2015.07.005 · Cited by 20
Genest, J. J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70305-1 · Cited by 20
Wańkowicz, P., Nowacki, P., & Gołąb-Janowska, M. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.77546 · Cited by 20
Jun, D., Schumacher, M. M., Hwang, S., Kinch, L. N., Grishin, N. V., & DeBose‐Boyd, R. A. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000551 · Cited by 20
Ramadan, W. H., & Kabbara, W. K. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s79198 · Cited by 19
Statin Use and Cognitive Function: Population-Based Observational Study with Long-Term Follow-Up
Joosten, H., Visser, S. T., van Eersel, M. E. A., Gansevoort, R. T., Bilo, H. J. G., Slaets, J. P. J., & Izaks, G. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115755 · Cited by 19
Cholesterol trials and mortality
Warren, J. B., Dimmitt, S. B., & Stampfer, H. G. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12945 · Cited by 18
Pearson, O. R., Segal, L., & McDermott, R. A. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-185 · Cited by 18
Weidmann, L., Obeid, S. N., Mach, F., Shahin, M., Yousif, N., Denegri, A., Müller, O., Räber, L., Matter, C. M., & Lüscher, T. F. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.050 · Cited by 18
Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia
Bove, M., Fogacci, F., & Cicero, A. F. G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1381085 · Cited by 18
Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia
Vissers, M. N., Trip, M. D., Pritchard, P. H., Tam, P., Lukić, T., der Velden, M. G. M. D. S., de Barse, M. M. J., & Kastelein, J. J. P. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0462-1 · Cited by 18
Wańkowicz, P., Staszewski, J., Dȩbiec, A., Nowakowska-Kotas, M. M., Szylińska, A., & Rotter, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061223 · Cited by 18
Anaesthetic techniques to prevent perioperative stroke
Engelhard, K. (2013) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e3283608239 · Cited by 17
Sekaran, N. K., Sussman, J. B., Xu, A., & Hayward, R. A. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-90 · Cited by 17
Statins may reduce femoral osteolysis in patients with total Hip arthroplasty
Lübbeke, A., Garavaglia, G., Rothman, K. J., Bonvin, A., Roussos, C., Miozzari, H. H., & Hoffmeyer, P. J. (2012) · Journal of Orthopaedic Research® · doi:10.1002/jor.22262 · Cited by 17
Wang, Q., & Liang, C. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000914 · Cited by 17
on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0545-2 · Cited by 16
Statins and safety: can we finally be reassured?
Kohli, P., & Cannon, C. P. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61544-4 · Cited by 16
ACEI/ARB Underused in Patients with Type 2 Diabetes in Chinese Population (CCMR-3B Study)
Xie, Q., Hao, C., Ji, L., Hu, D., Zhu, T., Li, X., Qin, D., & Zhang, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116970 · Cited by 16
Management of hyperlipidemia with statins in the older patient
Aronow, W. S. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.433 · Cited by 16
Cumulative in-trial and post-trial effects of blood pressure and lipid lowering
Hirakawa, Y., Arima, H., Rodgers, A., Woodward, M., & Chalmers, J. P. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001233 · Cited by 16
Pitavastatin: finding its place in therapy
Ose, L. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310389227 · Cited by 15
Hypolipidaemic Effects of Gymnema Sylvestre on High Fat Diet Induced Dyslipidaemia in Wistar Rats
Singh, D. K. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/27430.9859 · Cited by 15
Robinson, J. G., Heistad, D. D., & Fox, K. A. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.023 · Cited by 15
STATIN USE AND THE INCIDENCE OF AGE-RELATED MACULAR DEGENERATION
Eshtiaghi, A., Popovic, M. M., Sothivannan, A., Muni, R. H., & Kertes, P. J. (2022) · Retina · doi:10.1097/iae.0000000000003398 · Cited by 14
Statins and Cognition in Parkinson’s Disease
Deck, B. L., Rick, J. H., Xie, S. X., Chen‐Plotkin, A. S., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N. A., Trojanowski, J. Q., & Weintraub, D. A. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171113 · Cited by 14
Brotons, C., Moral, I., Fernández, D., Puig‐Asensio, M., Calvo‐Bonacho, E., Muñoz, P., Romero, C. C., & Quevedo-Aguado, L. (2018) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.05.028 · Cited by 14
Waßmuth, S., Rohe, K., NOACK, F., Noutsias, M., Treede, H., & Schlitt, A. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s197089 · Cited by 14
Jafari, N., Bahreini, N., Dehghani, A., Lak, Y., Mirmohammadali, S. N., Samavat, S., Shami, A., Karimizand, M., Goudarzi, M. A., & Asbaghi, O. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3555 · Cited by 12
A Point‐by‐Point Response to Recent Arguments Against the Use of Statins in Primary Prevention
Joshi, P. H., Chaudhari, S., Blaha, M. J., Jones, S. R., Martin, S. S., Post, W. S., Cannon, C. P., Fonarow, G. C., Wong, N. D., Amsterdam, E. A., et al. (2012) · Clinical Cardiology · doi:10.1002/clc.22016 · Cited by 13
Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia
Bosomworth, N. J. (2016) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2016.06.160085 · Cited by 14
Hu, P. L., Tan, C. Y.-L., Nguyen, N. H. L., Wu, R. R., Bahadin, J., Nadkarni, N. V., & Tan, N. C. (2022) · Singapore Medical Journal · doi:10.11622/smedj.2022067 · Cited by 13
Zachariah, J., & Johnson, P. K. (2014) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2014.08.004 · Cited by 12
Doggrell, S. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.696098 · Cited by 12
Li, Y., Wu, Y., Li, Y., Lu, M., Ding, C., & Dong, Z. (2019) · Molecules · doi:10.3390/molecules24091666 · Cited by 13
The role of statins in the regulation of breast and colorectal cancer and future directions
Dang, Y., Zhang, Y., & Wang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1578345 · Cited by 12
Statin Therapy for Primary and Secondary Prevention in Older Adults
Bao, A., & Karalis, D. G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01257-9 · Cited by 12
Evidence-Based Prescribing of Statins: A Developing World Perspective
Ong, H. T. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030050 · Cited by 12
Metadata
- Authors
- Heart Protection Study Collaborative Group
- Corresponding author
- Heart Protection Study Collaborative Group
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 378
- Issue
- 9808
- Pages
- 2013-2020
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3242163
- OpenAlex
- W2133184701
- Cited by
- 373
- References
- 17
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 15 · 2023: 17 · 2022: 14 · 2021: 13 · 2020: 14 · 2019: 20 · 2018: 25 · 2017: 17 · 2016: 28 · 2015: 29 · 2014: 27 · 2013: 41 · 2012: 38
- FWCI
- 38.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Medical Research Council (MC_EX_G0801669)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- statin therapy, simvastatin, LDL cholesterol lowering, long-term efficacy, vascular death, major vascular events, cancer incidence, post-trial follow-up, Heart Protection Study, high-risk patients, statin safety, lipid-lowering therapy, secondary prevention of cardiovascular disease, long-term follow-up, cardiovascular risk reduction
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cholesterol, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Myocardial Revascularization, Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
